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Abstract
Various half-sandwich ruthenium(II) arene complexes and rhodium(III) arene complexes have been intensively investigated 
due to their prominent anticancer activity. The interaction of the organometallic complexes of Ru(η6-p-cymene) and Rh(η5-
C5Me5) with human serum albumin (HSA) was studied in detail by a combination of various methods such as ultrafiltration, 
capillary electrophoresis, 1H NMR spectroscopy, fluorometry and UV–visible spectrophotometry in the presence of 100 mM 
chloride ions. Binding characteristics of the organometallic ions and their complexes with deferiprone, 2-picolinic acid, 
maltol, 6-methyl-2-picolinic acid and 2-quinaldic acid were evaluated. Kinetic aspects and reversibility of the albumin bind-
ing are also discussed. The effect of low-molecular-mass blood components on the protein binding was studied in addition 
to the interaction of organorhodium complexes with cell culture medium components. The organometallic ions were found 
to bind to HSA to a high extent via a coordination bond. Release of the bound metal ions was kinetically hindered and could 
not be induced by the denaturation of the protein. Binding of the Ru(η6-p-cymene) triaqua cation was much slower (ca. 24 h) 
compared to the rhodium congener (few min), while their complexes interacted with the protein relatively fast (1–2 h). The 
studied complexes were bound to HSA coordinatively. The highly stable and kinetically inert 2-picolinate Ru(η6-p-cymene) 
complex bound in an associative manner preserving its original entity, while lower stability complexes decomposed partly 
or completely upon binding to HSA. Fast, non-specific and high-affinity binding of the complexes on HSA highlights their 
coordinative interaction with various types of proteins possibly decreasing effective drug concentration.
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CZE  Capillary zone electrophoresis
DG  Dansylglycine
dhp  1,2-Dimethyl-3-hydroxy-pyridin-4(1H)-one, 
deferiprone
HMM  High molecular mass
HSA  Human serum albumin
LMM  Low molecular mass
maltol  3-Hydroxy-2-methyl-pyran-4(1H)-one
PBS’  Modified phosphate buffered saline
pic  2-Picolinic acid
PTA  1,3,5-Triaza-7-phosphaadamantane
RhCp*  Rh(η5-C5Me5)
RM175  [Ru(II)(η6-biphenyl)(ethylenediamine)Cl]+
RuCym  Ru(η6-p-cymene)
UV–vis  UV–visible
WF  Warfarin
Introduction
During the development of metal compounds for medici-
nal purposes, organometallics have been shown to exhibit 
promising activity in various diseases [1–5]. In particular, 
half-sandwich Ru(II)-arene complexes have attracted atten-
tion, since some representatives show significant anticancer 
activity and non-cross resistance with cisplatin. [3, 6–8]. The 
interest for organoruthenium compounds in cancer treatment 
became more pronounced as the clinically relevant Ru(III) 
drug candidates NKP1339 and NAMI-A were reported to 
exert their anticancer effect in the reduced Ru(II) forms 
[9]. Among Ru(II) compounds [Ru(II)(4,4′-dimethyl-2,2″-
bipyridine)(2-((2′,2′’:5′’,2′’’-terthiophene)-imidazo[4,5-f] 
[1,10] phenanthroline))] (TLD1433) has completed a phase 
1 clinical trial for treating bladder cancer with photodynamic 
therapy [10]. [Ru(II)(η6-p-cymene)(PTA)Cl2] (RAPTA-C; 
PTA = 1,3,5-triaza-7-phosphaadamantane) and the RAED 
type [Ru(II)(η6-biphenyl)(ethylenediamine)Cl]+ (RM175) 
are considered the lead structures for antitumor half-sand-
wich Ru(II)-arene compounds [1, 5, 11, 12]. Complexes 
of the isoelectronic congener Rh(III)(η5-C5Me5) showing 
promising in vitro anticancer activity have also been inten-
sively investigated [13, 14]. Early reports on the mechanism 
of action of anticancer Ru(III) complexes suggested interac-
tion with DNA, similar to cisplatin, which was believed to be 
ultimately responsible for the anticancer activity. Even in the 
case of Ru(II)-arene complexes, DNA nucleobases were pri-
mary suspects in their cytotoxic activity [15–18]. Although 
the actual mechanisms of action of these complexes are still 
not clarified, in recent years, more studies evidenced that 
DNA is not necessarily the only and/or primary target for 
ruthenium organometallics. Currently, the role of intra and 
extracellular proteins as possible targets of organoruthenium 
and related complexes is widely investigated [19].
Binding of these complexes to proteins is of consider-
able interest not only because of the exploration of feasible 
modes of action but explanation of side effects and pharma-
cokinetic behavior becomes possible as well. Amino acid 
side chains of proteins, similarly to DNA nucleobases, pro-
vide versatile coordinating sites for metal ions. The question 
is how these Ru(η6-arene) and Rh(η5-arenyl) complexes can 
interact with protein donor groups. Thus, our research inter-
ests are in the area of the following: (i) what kind of adducts 
can be formed, (ii) which are the preferred sites and, (iii) 
what are the time frame and the extent of these interactions. 
If these complexes are administered intravenously, potential 
first binding partners in vivo are blood constituents such as 
the non-specific transport protein albumin. In case of oral 
administration after the absorption from the gastrointestinal 
tract, the drug also reaches the systemic circulation. In both 
cases, binding to transport proteins, e.g., to human serum 
albumin (HSA) has a profound effect on the distribution, 
metabolism and excretion of a compound. This interaction 
can be advantageous due to the enhanced permeability and 
retention effect in solid tumor tissues resulting in the accu-
mulation of protein-bound drugs close to the cancer cells 
[20]. On the other hand, an irreversible protein binding can 
decrease effective drug concentration and may be respon-
sible for adverse effects as well [21, 22]. Notably, the cell 
culture media used for the in vitro cytotoxic measurements 
also contain albumin and other serum proteins, thus interac-
tion with these proteins in the medium can also affect the 
original integrity of the complex.
HSA binding of anticancer metallodrugs is a widely 
investigated area and numerous papers were published for, 
e.g., Pt(II) [23–26], Ru(III) [27–31] and Ga(III) [32–34] 
complexes. In vitro studies on direct albumin binding of half-
sandwich organometallic complexes are also reported [35, 
36], however, in vivo results are rarely published [37]. Klose 
et al. have investigated recently the distribution of two half-
sandwich p-cymene complexes ([Ru(η6-p-cymene)(plec-
statin)Cl] and [Os(η6-p-cymene)(plecstatin)Cl]) in mouse 
blood serum by size-exclusion chromatography–inductively 
coupled plasma–mass spectrometry (SEC–ICP–MS). Free 
drug was not observed in any of the samples indicating rapid 
protein binding of the metallodrugs. A larger portion of 
these drugs (ca. 75%) was found in the albumin/transferrin 
fraction underlying the importance of interactions towards 
HSA as well [37].
Sadler et al. reported the coordination of the rather acces-
sible surface imidazole nitrogen donors (histidines) of 
HSA to the Ru(II) center in the case of RM175 [38], while 
adduct formation with cytochrome c was thought to involve 
the N-terminus or carboxylic acid side chains on the pro-
tein [39]. Moreover, several single crystal X-ray structures 
confirm coordinative binding of various types of Ru(η6-p-
cymene) and Rh(η5-C5Me5) complexes towards proteins like 
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lysozyme, apo-ferritin or histone proteins [40–48], which are 
not believed to be all the primary targets for these organome-
tallic compounds but may provide insight on the types of non-
specific adducts formed with proteins. The albumin binding of 
Rh(η5-C5Me5) and its complexes formed with 1,2-dimethyl-
3-hydroxy-pyridin-4(1H)-one (deferiprone, dhp), ethylenedi-
amine and 2,2′-bipyridine (bpy) was formerly investigated in 
our research group. Our results suggested that the interaction 
with HSA can proceed in both dissociative (binding of the 
organometallic fragment only) and non-dissociative manner 
depending most probably on the thermodynamic stability 
of the metal complexes [49]. HSA is a key protein in blood 
transport and may serve as a universal protein model as well. 
Herein we provide a comprehensive picture on the interac-
tions of various Rh(η5-C5Me5), Ru(η6-p-cymene) complexes 
with HSA. Studied compounds are the organometallic cations 
[Rh(η5-C5Me5)(H2O)3]2+ and [Ru(η6-p-cymene)(H2O)3]2+ 
themselves and their complexes formed with bidentate ligands: 
3-hydroxy-2-methyl-pyran-4(1H)-one (maltol), dhp, 2-pico-
linic acid (pic), 6-methyl-2-picolinic acid (6-Mepic) and 
quinoline-2-carboxylic acid (2-quinaldic acid) (Chart 1). Our 
goal is to provide a comprehensive overview of the binding 
strength, location, and kinetics and the binding mode and its 
reversibility. The effect of low-molecular-mass components on 
the protein binding and the stability of selected complexes in 
a minimum essential cell culture medium were tested as well. 
Efficiency and possible shortages of techniques applied here, 
namely 1H NMR-, UV–visible and fluorescence spectrosco-
pies; ultrafiltration–UV–visible and capillary zone electropho-
resis, are critically discussed as well.
Experimental
Chemicals
[Rh(η5-C5Me5)(µ-Cl)Cl]2, [Ru(η6-p-cymene)(µ-Cl)Cl]2, 
maltol, dhp, pic, 6-Mepic, 2-quinaldic acid, bpy warfarin 
(WF), dansylglycine (DG), sodium dodecyl sulfate (SDS), 
citric acid, sodium lactate, l-amino acids: histidine (His), 
methionine (Met), cysteine (Cys), serine (Ser), and inorganic 
salts KCl,  KH2PO4,  NaH2PO4,  Na2HPO4 were products of 
Sigma-Aldrich or Reanal in puriss quality. HSA (A8763, 
essentially globulin free) and Roswell Park Memorial Insti-
tute (RPMI) 1640 cell culture medium was purchased from 
Sigma-Aldrich.
Stock solutions and sample preparation
Milli-Q water was used for preparation of stock solutions 
and samples. Exact concentrations of stock solutions of the 
ligand and the organometallic cations were determined by 
pH-potentiometric titrations according to procedure pub-
lished in our former work [50]. Organometallic complexes 
were obtained by mixing the corresponding ligand and metal 
precursor ([Rh(η5-C5Me5)(µ-Cl)Cl]2, [Ru(η6-p-cymene)
(µ-Cl)Cl]2) in 1:0.5 molar ratio in water; solutions were 
equilibrated for 24 h. HSA stock solutions were prepared 
in modified phosphate buffered saline (PBS′), pH 7.40 con-
taining 12 mM  Na2HPO4, 3 mM  KH2PO4, 1.5 mM KCl 
and 100.5 mM NaCl. Concentration of the  K+,  Na+ and 
 Cl‒ ions corresponds approximately to that of the human 
blood serum. Residual citrate content of HSA was removed 
by repeated ultrafiltration of the protein stock solution, and 
its concentration was calculated from its UV absorption: 
λ280 nm(HSA) = 36,850 M−1 cm−1 [51]. Stock solutions of 
WF and DG were prepared as described previously [31]. 
Samples containing RhCp* and RuCym compounds were 
incubated for 2 and 24 h, respectively, prior to the meas-
urements, or the reaction kinetic was followed. All samples 
were prepared in PBS’ and incubated at 25 ± 0.1 °C and 
measurements were carried out at this temperature.
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[Ru(η6-p-cymene)(H2O)3]2+
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[Rh(η5-C5Me5 (H2O)3]2+
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(X,Y) = (O,N)
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M X
Y
Chart  1  Chemical structures and abbreviations of the organometal-
lic triaqua cations of Ru(η6-p-cymene) (RuCym) and Rh(η5-C5Me5) 
(RhCp*), general formula of the studied complexes and structures 
of the complex forming bidentate ligands in their neutral forms: 
1,2-dimethyl-3-hydroxy-pyridin-4(1H)-one (deferiprone, dhp), 
3-hydroxy-2-methyl-pyran-4(1H)-one (maltol), 2-picolinic acid (pic), 
quinoline-2-carboxylic acid (2-quinaldic acid) and 6-methyl-2-pico-
linic acid (6-Mepic)
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1H NMR spectroscopy
1H NMR spectroscopic studies were carried out on a Bruker 
Avance III HD instrument. All spectra were recorded with 
the WATERGATE water suppression pulse scheme using 
DSS internal standard. To study the interaction with HSA 
and the RPMI 1640 components 1H NMR spectra were 
recorded for samples containing 1 mM organometallic com-
pound and 0.5 mM HSA or 1.25-fold diluted RPMI 1640 in 
PBS’ at 10% (v/v)  D2O content.
Spectrofluorometry
Fluorescence spectra were recorded on a Hitachi-F4500 
fluorometer in 1 cm quartz cell. Samples contained 1 μM 
HSA and various HSA-to-metal compound ratios (from 1:0 
to 1:20) were used. In the site marker displacement experi-
ments, the HSA-to-site marker (WF or DG) ratio was 1:1 
and the concentration of the compounds varied. The excita-
tion wavelengths were 295, 310 or 335 nm depending on 
the type of the experiment and the emission was read in the 
range of 310–650 nm. The conditional binding constants 
(log K′) were computed with the computer program PSE-
QUAD [52] as described in our previous works [31, 53]. The 
effect of low-molecular-mass (LMM) components on the 
albumin binding of Ru and Rh compounds was monitored 
in samples containing 1 μM HSA, 10 μM metal complex and 
LMM component mixture or only one of these components 
corresponding to their blood serum concentration: Ser (~ 100 
μM), His (~ 77 μM), Met (~ 77 μM) and Cys (~ 33 μM), cit-
rate (~ 99 μM) and lactate (~ 1.5 mM). Samples containing 
Cys were kept in a strictly oxygen-free atmosphere. Calcula-
tions always were based on data obtained from at least two 
independent measurements. Corrections for self-absorbance 
and inner filter effect were necessary, since the emitted light 
was partly absorbed by the compounds. Corrections were 
carried out according to the following equation [54]:
 where Icorr and Imeas are the corrected and measured fluo-
rescence intensities, AEX and AEM are the absorbance values 
at the excitation and emission wavelengths in the samples, 
respectively.
UV–visible spectrophotometry
A Hewlett Packard 8452A and an Agilent Carry 8454 diode-
array spectrophotometer were utilized to record the UV–vis-
ible (UV–vis) spectra in the interval 190–820 nm. The path 
length (l) was 1 cm. For the reaction kinetic studies, a tan-
dem cuvette with two chambers was used. Measurements 
were performed at various metal complex concentrations 
Icorr = Imeas × 10
(AEX+AEM)∕2,
(between 20 and 200 μM), and various protein-to-complex 
ratios (from 0.02:1 to 2:1) were applied. UV–vis spectra 
presented in this paper are subtracted by the spectrum of 
reference albumin sample in all cases in favor of the bet-
ter interpretation of the results. Reference spectra for the 
complexes and their components (ligand and organometal-
lic cation) were recorded as well. Excel Solver (Microsoft 
Office 2016) was utilized for deconvolution of the absorb-
ance spectra.
Ultrafiltration
Samples were separated by ultrafiltration through 10 kDa 
membrane filters (Millipore, Amicon Ultra-0.5), in low- 
and high-molecular-mass (LMM and HMM) fractions with 
the help of an Eppendorf MiniSpin plus centrifuge (rela-
tive centrifugal force ∼ 1500g, 5–10 min). Three different 
types of experiments were carried out: samples contained 
(1) 50 μM HSA and 50–430 μM organometallic compound; 
(2) ~ 500 μM organometallic cation and 8–50 μM HSA; (3) 
reversibility of the protein binding was followed by con-
secutive washing and filtration steps and then by filtration 
of samples after addition of 0.5% (m/m) SDS. The concen-
tration of the non-bound compounds in the LMM fractions 
was determined by UV–Vis spectrophotometry by compar-
ing the recorded spectra to those of reference samples with-
out the protein. When the complex partly decomposed due 
to the protein binding, the free ligand was also detected in 
the LMM fraction. In this case, the recorded spectrum was 
deconvoluted with the use of the molar absorbance spectra 
of the ligand and metal complex by Excel Solver (Microsoft 
Office 2016). The HMM fraction was studied in a similar 
way for some samples as well.
Capillary zone electrophoresis
Measurements were performed on a G7100 capillary elec-
trophoresis system (Agilent Technologies, Waldbronn, Ger-
many) equipped with a diode-array detector (210–600 nm). 
For all experiments, fuse silica capillaries of 48 cm total 
length (50 μm inner diameter) were used (BGB Analytik). 
Phosphate buffer (20 mM, pH 7.40) was the background 
electrolyte (BGE). The conditioning process of new capil-
laries started with HCl (0.1 M) and  H2O followed by NaOH 
(0.1 M) and  H2O for 20 min each and was completed with 
flushing of the BGE for 40 min. A similar procedure was 
applied for daily preparation of the capillary although with-
out purging with HCl. To ensure the steady baseline, the 
capillary was flushed with BGE (2 min) before each run and 
was rinsed with NaOH (0.1 M; 1.5 min),  H2O (1.5 min), and 
BGE (2 min) after each separation. The sample tray and the 
capillary were kept at a constant temperature of 25 °C. Sam-
ples were injected hydrodynamically at 50 mbar for 15 s, 
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and voltage of 30 kV was applied for the separation process 
producing a current of ca. 44 μA. Sample run time was set 
to 6 min. Electropherograms were recorded and evaluated 
by the program ChemStation (Agilent Technologies). The 
detection wavelength was set to 280 or 260 nm depending 
on the samples studied. Samples contained ca. 200 μM orga-
nometallic compound and various concentrations of HSA 
(10–100 μM) in PBS′. The peak integrals of the non-bound 
complex and ligand were used to obtain their concentrations 
using external calibration. UV–Vis spectra belonging to all 
peaks were collected as well.
Results
Interaction of Rh(η5‑C5Me5) compounds with RPMI 
1640 cell culture medium
Prior to the investigation of the interactions of biomolecules 
with organorhodium and organoruthenium compounds, the 
knowledge of their actual forms at physiological condi-
tions is of critical importance to get adequate conclusions. 
Dissolving the organometallic precursor ([Rh(η5-C5Me5)
(µ-Cl)Cl]2 in water at pH 7.40 the triaqua cation [Rh(η5-
C5Me5)(H2O)3]2+ and its hydrolysis products [(Rh(η5-
C5Me5))2(μ-OH)2]+ and [(Rh(η5-C5Me5))2(μ-OH)3]2+ are 
formed; their actual quantity depends on the analytical 
concentration of the dissolved precursor. In the presence of 
0.1 M chloride ion, corresponding to the chloride concentra-
tion in blood serum, aqua and hydroxido ligands are partly 
displaced by chloride ions. Namely, a mixture of species is 
present in the solution. The ruthenium precursor behaves 
similarly. For this reason, these species (if there is no need 
for closer definition) are referred generally as RhCp* for 
Rh(η5-C5Me5) and RuCym for Rh(η6-p-cymene) species. 
RhCp* and RuCym hydrolyze in about 23% and 100%, 
respectively, at physiological conditions at 50 μM concen-
tration [50, 55].
The complexes of the bidentate ligands presented in 
Chart 1 were obtained by mixing the precursors and the 
ligands in 0.5:1 ratio in water and by this way the aqua 
complexes formed (Chart 1). Although, in chloride-con-
taining media, chlorido complexes are present to some 
extent as well, therefore the leaving group is generally 
not specified in our complex structures and are referred 
to as, e.g., RhCp*(dhp) or RuCym(pic). Dhp as an (O,O) 
donor ligand forms somewhat lower stability complexes 
with the two organometallic cations compared to the (O,N) 
donor pic. Dhp complexes of both RhCp* and RuCym 
dissociate in about 4–5% at pH 7.40 and 50 μM complex 
concentration at I = 0.2 M KCl, while pic complexes are 
more stable and less than 0.5% dissociate under the same 
conditions [56–58]. These values may somewhat differ at 
physiological (100 mM) chloride ion concentration, as 
chloride ions can compete with the coordinating ligands 
and suppress the complex formation. RuCym(maltolato) as 
an example for a low stability complex (29% decomposed 
under the condition vide supra) was also selected [59], and 
complexes of picolinate derivatives 6-Mepic and 2-qui-
naldic acid formed with RhCp* characterized by higher 
lipophilicity than the pic complex were involved in our 
investigations as well [60] (constants regarding the com-
plex stability, chloride affinity and lipophilicity data are 
listed in Table S1).
In vitro cytotoxicity studies are always carried out in 
cultured media, which are produced in different composi-
tions according to the actual use. Some compounds are 
essential and universal components of these mixtures. 
All kinds of minimum essential media (MEM or Eagle’s 
MEM) contain phosphate and bicarbonate buffered saline, 
inorganic ions  Ca2+,  Mg2+,  K+,  Na+, essential l-amino 
acids (histidine, (iso)leucine, lysine, methionine, pheny-
lalanine, threonine, tryptophan, valine) and some non-
essential l-amino acids (e.g., arginine, cystine, tyrosine). 
While phosphate was proven to be a ‘safe’ buffer for these 
organometallic compounds in our preliminary measure-
ments, hydrogencarbonate and amino acids are potential 
ligands of organorhodium and organoruthenium cations 
and can be effective competitors of the original ligand set 
in this kind of complexes [61–64]. The medium applied 
here was RPMI 1640, containing 20 alpha amino acids, 
vitamins, glucose, glutathione and phenol red.
1H NMR spectra in Fig.  1 show the interaction of 
organorhodium ion and its dhp or pic complexes with 
RPMI 1640 components. The original RhCp*(dhp) com-
plex is completely dissociated, dhp and (most probably) 
coordinating water as well are replaced by RPMI 1640 
components, which results in the appearance of the same 
peak set for  C5Me5 methyl protons like in case of RhCp* 
itself, and no mixed-ligand complex formation can be 
observed. A similar result was obtained with related com-
plex RhCp*(acetylacetonato) in our former work [65]. The 
pic complex reacts somewhat differently: about 75% of the 
ligand is liberated here as well, but the rest is coordinated 
to the metal ion. Splitting and shifting of the  C5Me5− pro-
ton signal, however, suggest mixed-ligand complex for-
mation with medium component(s). In cytotoxicity meas-
urements, the tested compounds are dissolved typically 
in micromolar concentrations in cell medium, and more 
pronounced decomposition of the original complexes is 
expected under these conditions. Consequently, cytotoxic-
ity measured for lower stability complexes (e.g., the dhp 
or acac complexes) did not exceed the sum of efficacy 
measured for organorhodium ion (coordinated to medium 
components) and the ligand (if it is active) separately [56, 
65].
708 JBIC Journal of Biological Inorganic Chemistry (2019) 24:703–719
1 3
Cultured media often contain ca. 10% heat-inactivated 
fetal bovine serum. Serum proteins including albumin as 
potential reaction partners for metal complexes are present 
in these samples as well. Studying the interaction of these 
organometallic compounds with proteins, especially with 
human serum albumin is important in other aspects as well, 
which are discussed in the next sections in detail.
Binding of (Rh(η5‑C5Me5) and (Ru(η
6‑p‑cymene) 
to human serum albumin
Binding of anticancer metallodrugs to HSA is of consid-
erable interest, as it may have a significant effect on the 
biodistribution, toxicity and side effects. Moreover, HSA- 
and HSA-bound drugs can accumulate in malignant and 
inflamed tissues such as solid tumors as a consequence of 
the enhanced permeability and retention effect, which can 
be exploited for tumor targeting as well [20]. Organome-
tallic fragments RhCp* and RuCym (Chart 1) per se exert 
no antitumor activity, however a deeper knowledge on their 
interaction with albumin is a mandatory prerequisite for 
understanding the binding mechanism of their complexes 
to this protein.
The binding mode and binding strength of the organorho-
dium ion (without coordinated ligands) on HSA were inves-
tigated in our former work [49]. However, albumin binding 
of organoruthenium ion was not characterized adequately 
in solution, since only its binding at the hydrophobic site I 
(IIA subdomain) was reported [57]. This section provides a 
detailed kinetic, quantitative and qualitative description on 
the HSA binding of RhCp* and RuCym species.
Both organometallic cations displayed considerable 
changes in their UV–vis spectra in Fig. 2 in the presence 
of HSA. RhCp* showed a bi-phasic binding profile, where 
a fast (~ 5 min) process is followed by a much slower one 
(~ 24 h). Based on our ultrafiltration, and CZE studies, the 
binding is completed in the first few minutes, and the sub-
sequent spectral changes in Fig. 2a can be attributed most 
probably to structural rearrangement of the coordination 
sphere around the metal ion. On the contrary, binding of 
RuCym to the protein takes place about 24 h (Fig. 2b) con-
firmed by 1H NMR spectroscopic, ultrafiltration and CZE 
time-dependent measurements. The observed remarkably 
different binding rates of the two organometallic cations 
partly can be explained by their different solution spe-
ciation at pH 7.40. RuCym is present in 100% as dimeric 
hydroxido species [(RuCym)2(μ-OH)3]+, which is known 
to be kinetically more inert compared to the aqua cation, 
while in case of RhCp* there is ca. 55% non-hydrolyzed 
[Rh(η5-C5Me5)(H2O)3]2+ in solution under this condition 
[50, 55, 66]. Furthermore, as a result of the markedly 
increased trans effect of the anionic pentamethylcyclo-
pentadienyl ligand in comparison to the neutral p-cymene 
ligand, typical substitution rates for RhCp* complexes 
are several orders of magnitude higher (~ 102–103  s−1 for 
 H2O exchange in monoaqua complexes) than for analo-
gous Ru(II)-arene anticancer compounds (~ 10−3–10−1  s−1) 
[67, 68]. In subsequent experiments, samples containing 
RuCym or RhCp* were always measured after 24 h and 
1 h waiting time, respectively.
It should be mentioned that commercially available lyo-
philized HSA may contain residues of citric acid as anti-
coagulant additive of the original blood stock. The pres-
ence of citrate can be detected by 1H NMR spectroscopy 
(Fig. S1). Citrate is a coordinating ligand of RuCym [69] 
(and probably of RhCp* as well), consequently peaks of 
the citrate complexes could be observed in 1H NMR spectra 
of citrate-contaminated protein samples (Fig. S1). Further-
more, we have found that presence of citric acid increases 
the binding rate of RuCym towards albumin about four to 
fivefold. Therefore, citrate content of HSA stocks was always 
checked by 1H NMR spectroscopy and, if it was necessary, 
HSA stock solutions were purified by ultrafiltration.
HSA is able to accommodate 8–9 eq RhCp* as it was 
reported in our former work [49], although these numbers 
do not seem to be the upper limit of available binding sites 
for RhCp*. The results of ultrafiltration studies presented 
in Fig. 3 reveal nearly quantitative binding of even 20 eq of 
cations on HSA and a maximal number of ca. 24 ± 3 RhCp* 
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can be bound by the protein. Practically quantitative bind-
ing of RuCym can be observed up to 9 eq of metal ion, and 
binding capacity of HSA is saturated with ca. 14 ± 1 eq of 
RuCym.
Both RhCp* and RuCym may bind to HSA in a coordina-
tive manner, but a striking difference is seen in the number 
of coordination sites. Coordination of His imidazole nitro-
gen is suggested by Sadler et al. in the interaction of HSA 
with RM175 complex [38]. HSA contains 16 His residues as 
possible coordination sites, however, it is less, than the max-
imal number of bound RhCp*, and some of these histidine 
nitrogens may be not easily accessible for the organometallic 
cations. Interaction with sulfur donor side chains of Met and 
Cys can be assumed as well based on the works of Briš et al. 
and Hu et al. [70, 71]. Free thiol groups of small ligands 
Cys, glutathione and N-acetyl-cysteine show high affinity 
towards RuCym(PTA) complexes [70], while the single free 
thiol group in HSA (Cys-34) was reported to undergo oxida-
tion during its interaction with [RuCym(ethylenediamine)
Cl]+ resulting in the formation of sulfinato complex with-
out dissociation of the ethylenediamine ligand [71]. In the 
same work surface-exposed His-128, His-247, His-510 and 
Met-298 are also denoted as coordination sites of Ru(arene) 
complexes [71]. X-ray single crystal structures reported for 
protein–RuCym complex adducts often show coordination 
of amino acids His or Glu to the metal center [40–46], and 
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coordination of Lys, Arg, Asp and Cys side chains occurs 
as well [41, 46, 47]. Coordination of one or two of these 
side chains is typical, and the loss of p-cymene ligand can 
be detected in some cases as well [40, 41, 47]. Apo-ferritin 
coordinated [(NHis,NHis,OGlu)] is the only reported struc-
ture, where coordination sphere of RuCym is saturated 
by the donor groups of the protein [41]. To the best of our 
knowledge, there is only one structure reported on protein-
coordinated RhCp*; here two organorhodium fragments are 
bound to His-112 and His-121 imidazoles, respectively, in 
streptavidin [48]. Namely, mono or bidentate coordination 
seems to be feasible in HSA, while binding of HSA donor 
groups in tridentate mode is most probably sterically less 
favored. Involvement of S-donor Cys-34, Met (6 residues in 
HSA); O-donor glutamate (62), aspartate (36) or N-donor 
lysine (59) or arginine (24) side chains is feasible in binding 
of high excess of RuCym and RhCp*.
It is difficult to get a clue on the binding environment 
of the organometallic cations in solution; however, UV–vis 
spectra can provide some information about the coordina-
tion sphere(s) forming around the organometallic cations 
inside the protein. Individual molar spectrum of the ‘albu-
min-bound’ forms can be obtained both in steady-state 
UV–vis measurements (Fig. 2c) and via examining albu-
min-bound fraction of ultrafiltered or electrophoretically 
separated samples (Fig. S2). As Fig. 2c shows, dinuclear 
[(RuCym)2(μ–OH)3]+ transforms into a typical mononu-
clear complex bound form, and two charge-transfer (CT) 
bands develop with λmax = 310 nm (εmax = 1100 M−1cm−1) 
and 382 nm (εmax = 670 M−1cm−1), which did not depend 
significantly on the Ru-to-HSA ratio applied. Notably, the 
recorded spectra did not indicate the loss of p-cymene ligand 
from the Ru(II) center (see details in Refs. [72, 73]). More 
detailed qualitative information can be obtained on the albu-
min-bound form of RhCp* (Fig. 2c), where λmax = 356 nm 
and εmax = 2800 M−1 cm−1 values of the forming protein 
complex can be compared to those of various complexes 
of bidentate ligands studied formerly in our research group 
(Table S2) [49, 50, 56, 60, 65, 72, 74, 75]. The correlation 
diagram presented in Fig. 4 (and Fig. S3) illustrates well 
the effect of each donor groups on the λmax and εmax values: 
λmax increases while εmax decreases tendentiously by chang-
ing the donor sets from (N,N) to (O,N) and then to (O,O). 
Additionally, coordination of the chlorido ligand in the third 
position induces red shifted λmax. According to the corre-
lation diagram, spectral parameters of HSA-bound RhCp* 
are close to the (N,N)(Cl)-type complexes (like complexes 
of ethylenediamine, bpy and their derivatives) raising the 
possibility of  (Nimidazole,Namide)-type coordination. These 
spectral parameters are practically unaltered between 1:1 
and 8:1 Rh-to-HSA ratio, but increasing the Rh excess from 
8:1 to 20:1 results in a gradual shift to λmax = 373 nm and 
εmax = 2270 M−1 cm−1, indicating the involvement of other 
types, probably (O,N), (O,O) and/or (O) donor sites into the 
binding of RhCp* on HSA as well. Another explanation can 
be the appearance of monodentate N-donor binding sites, 
which consequently resulted in red shifted λmax [76] as well.
Reaction rates of coordinating ligands with RuCym are 
strongly affected by the type of the donor atoms. Complex 
formation with (O,O) or (O,O,O) donor ligands is a fast 
process at physiological pH, while (N) and (N,N,N) donor 
ligands chelate the RuCym rather slowly (hours to days) [59, 
69, 76, 77]. Reaction rate with (O,N) donor bearing ligands 
mainly depends on the actual protonation state of the given 
donor atom, thus it also depends on the actual pH, and the 
interaction may take place from few minutes to several hours 
[57, 72]. In this view, slow coordination of protein (N)-donor 
group(s) to RuCym can be assumed.
Spectrofluorometric studies were carried out to investi-
gate the binding of RuCym at hydrophobic binding pockets 
site I (in subdomain IIA) and site II (in subdomain IIIA). 
Binding of RhCp* was formerly investigated by Trp-214 
quenching (at site I) and site marker displacement experi-
ments using WF and DG to follow interaction at sites I and 
II, respectively. High-affinity binding and fast binding rate 
(few min) were found for RhCp* at both sites [49]. RuCym 
displays slow binding at site I, as it was observed in the 
global binding studies (vide supra) as well and exerted affin-
ity at binding pocket I comparable to that of RhCp* (see 
Table 1). RuCym additionally interacts with free DG and 
quenches its fluorescence. Therefore, the binding at site II is 
observed but data can not be quantitatively evaluated. Since 
aqua complexes are partly chlorinated and can hydrolyze at 
pH 7.40, all protein binding constants determined here are 
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regarded as conditional stability constants and valid only 
under the given conditions. Considering the extremely high 
number of binding sites on HSA (which cannot be included 
in the calculations), the binding constants calculated here 
reflect the competitiveness of sites I and II against the other 
sites together with their affinity for the free metal com-
pounds. Namely, higher constants could be expected if the 
binding event at isolated sites could be studied. Slow binding 
of RuCym at site I indicates the involvement of (N) donor 
His-242 lining binding site I. Most probably RhCp* binds 
to the same His residue here, while the nature of coordinat-
ing donor group at site II is in question, since no His can be 
found among the residues evolving in this pocket [78].
Interaction of Rh(η5‑C5Me5) and Ru(η
6‑p‑cymene) 
complexes of dhp, pic and some related ligands 
with human serum albumin
Selection of the complexes was mainly governed by their 
well-characterized and somewhat different solution chemi-
cal properties and not by the otherwise poor cytotoxic effi-
cacy of the complexes. These selected complexes, however, 
are good models of in vitro active compounds, e.g., (O,O) 
donor flavone and naphtoquinone-type complexes of Ru(η6-
p-cym) or (O,N) donor 8-hydroxyquinoline or Schiff-base 
complexes of both metal ions [72, 80–85]. It was shown 
previously that interaction of the studied complexes with 
HSA is possible, both by loss of the bidentate ligand or by 
the loss of only chlorido leaving group [49]. The former one 
is considered as dissociative binding as the original ligand 
becomes unbound, while the latter one is referred here to as 
associative binding, i.e., binding of the ‘non-dissociated’ 
complex to the protein. Complex stability seems to play a 
key role in the type of the protein binding [49]. This way, 
it is useful to take a look at the reported solution chemical 
behavior of the studied complexes, since they could have a 
profound effect on their protein binding (Table S1). As it 
was mentioned (vide supra), the complex stability follows 
the following trend: maltol < dhp < picolinates at pH 7.4 
(Table S2).
First of all, global binding kinetics of the complexes 
towards albumin was studied by UV–Vis spectometry. 
RhCp* complexes interacted relatively fast with HSA 
and reaction rates did not depend on the complex-to-HSA 
ratios (Fig. S4a and b). The dhp and pic complexes were 
bound within 10 and 60 min, respectively, to the protein. 
RuCym(dhp) at the same time displays a completely differ-
ent behavior, a bi-phasic binding profile is characteristic with 
a fast, 10 min process and a much slower > 24 h phase. The 
equilibrium state could not be achieved even after 2 days, 
but longer studies are not reasonable from the physiological 
point of view; therefore subsequent samples were measured 
after 24 h waiting time. Samples with RuCym(pic) ultrafil-
tered after 4 h and 24 h indicated binding of the complex in 
a fairly similar extent in both cases without the release of 
Table 1  Conditional binding 
constants (log K′) of the 
compounds at binding sites 
I and II of HSA determined 
by spectrofluorometric 
quenching (log KQ′) and marker 
displacement log KWF′ and 
log KDG′ measurements [pH 
7.40 (PBS′); 25 ºC]
a log KQ′ = 5.25 reported for the related organometallic cation [Ru(η6-toluene)(H2O)3]2+ [57]
b Reported in Ref. [65]
c Could not be calculated because RuCym interacts with DG
d log KQ′ = 4.16 reported for the complex [Ru(η6-toluene)(pic)(H2O)]+ [57]
e Reported binding affinities of pic: log KQ′ = 4.18, log KWF′ = 4.05, log KDG′ = 3.65 [79]
f Reported in Ref. [49]
Site I Site II
Trp-214 quenching WF competition DG competition
RuCyma 5.60b – –
5.7 ± 0.1 5.9 ± 0.1 nmc
Complexed by
 Maltol 5.4 ± 0.1 5.8 ± 0.1 5.7 ± 0.1
 dhp 5.7 ± 0.1 5.7 ± 0.1 5.5 ± 0.1
 picd,e 4.3 ± 0.1 4.2 ± 0.1 4.2 ± 0.1
RhCp*f 5.8 6.1 5.8
Complexed by
 dhpf 5.9 6.2 5.8
 pice 5.1 ± 0.1 5.6 ± 0.1 5.1 ± 0.1
 6-Mepic 5.4 ± 0.1 5.9 ± 0.1 5.6 ± 0.1
 2-Quinaldic acid 5.5 ± 0.1 5.8 ± 0.1 5.5 ± 0.1
 Ethylenediaminef Weak Weak Weak
 bpyf Weak Weak Weak
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pic. Based on these findings, the Rh and Ru samples were 
incubated for 2 h and 24 h, respectively.
Mainly dissociative binding of RhCp*(dhp) was 
reported based on ultrafiltration and 1H NMR experi-
ments in our former work. Our new results obtained by 
UV–vis and CZE measurements were compared to that 
of previous ultrafiltration data. Figure 5 demonstrates 
the effect of increasing amounts of HSA on the UV–Vis 
spectra of RhCp*(dhp). Decomposition of the complex 
and appearance of free dhp and albumin-bound RhCp* 
were observed. According to former investigations, dhp 
itself does not interact with HSA [79]. Isobestic points 
in Fig. 5 indicate the predominance of only one kind 
of equilibrium process. The original recorded spectra 
could be deconvoluted to the spectra of HSA, HSA-
bound RhCp*, free dhp and free RhCp*(dhp) according 
to the hypothesized equilibrium RhCp*(dhp) + HSA ⇌ 
RhCp* − HSA + dhp. Deconvolution of the spectra gave 
a fairly good fit even at high complex excess (see Fig. 
S5). The CZE method turned out to be a particularly use-
ful tool for both quantitative and qualitative evaluations 
of the interaction. Samples for CZE measurements were 
prepared in PBS′, but 20 mM phosphate (pH 7.40) was 
chosen for BGE to avoid peak splitting and broadening 
caused by the fast equilibration of aqua and chlorido com-
plex forms in the electrophoretic capillary. Accordingly, 
the aqua complexes [M(ligand)(H2O)]+ (M=RhCp* or 
RuCym) were detected in CZE experiments. Each species 
separated well in the capillary: aqua complexes are + 1 
charged, dhp is neutral, pic is present in its anionic form 
and HSA is negatively charged under the given conditions. 
Calculated fractions computed from the peak areas of the 
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recorded electropherograms for unbound complex/ligand 
and then for the protein-bound complex are depicted in 
Fig. 6a. These fractions are in fairly good agreement with 
the results of UV–vis studies. Interestingly, ultrafiltration 
data revealed much lower quantities of free RhCp*(dhp) 
compared to CZE and UV–vis experimental data indicat-
ing the binding of non-dissociated RuCym(dhp) on HSA 
as well. The ultrafiltration experimental setup, however, 
differs from the other two methods basically, since the 
metal complex concentration was varied here in contrast 
to CZE and UV–Vis studies, where the complex concen-
tration was kept constant, and that of albumin was varied. 
Careful analysis of the absorbance spectra of the ‘protein 
peak’ in the electropherograms confirms the binding of 
RhCp* without the dhp ligand on HSA (Fig. S6). There-
fore, stacking of the complex to the filter is probable in 
ultrafiltration measurements resulting in overestimated 
quantities of bound RhCp*(dhp). Free fractions of dhp 
(which is equal to the bound fraction of organometallic 
ion) are well comparable in all three methods.
The interaction of RuCym(dhp) with HSA appears to be 
basically different from that of RhCp*(dhp). The bi-phasic 
binding profile mentioned before is due to the fast binding 
of the complex on HSA, and then slow release of dhp took 
place in the second phase as it is shown in Fig. 7. This pro-
cess did not lead to the complete release of dhp, ca. 20% of 
the ligand was liberated after 24 h incubation in CZE experi-
ment in a sample with 1:10 HSA-to-complex ratio. Namely, 
release of dhp occurs here as well, however, this phenom-
enon is more likely a kinetically governed process and only 
20–25% free dhp could be detected even after 24 h by both 
spectroscopic and separation techniques (1H NMR, CZE, 
ultrafiltration) at various HSA-to-complex ratios. Kinetic 
curves for this binding event were recorded at various 
HSA-to-complex ratios by UV–vis, which show increasing 
rates of dhp release at higher HSA concentrations (Fig. S4c).
Notably, at lower HSA concentrations, the free portions 
of the RuCym(dhp) complex obtained in ultrafiltration 
experiments are almost negligible compared to those of in 
CZE samples (Fig. 6c). In other words, ultrafiltration pre-
dicts remarkably high, ca. 98% binding of the metal com-
pounds (intact complex and organometallic ion together) 
at 1:0.12 HSA-to-complex ratio, while CZE provides 
only ca. 76%. UV–vis spectra in Fig. 8 recorded for the 
RuCym(dhp)–HSA system show only moderate absorbance 
increase in the wavelength range where free dhp absorbs 
light (λmax = 278 nm). This refers to the predominant binding 
of non-dissociated RuCym(dhp), and shows high similarities 
to those obtained for the albumin bound compound frac-
tion in the CZE studies (Fig. S6c). Spectra are not altered 
between 300 and 550 nm at 0.2–1 eq of HSA, namely five-
fold excess of metal complex seems to be bound quantita-
tively to albumin, and even at 20-fold excess (0.05 eq. HSA) 
spectra show stronger similarities to the protein-bound form 
than to the spectrum of the complex not bound to the pro-
tein (Fig. 8). More detailed evaluation of the spectra is not 
possible, since both the Ru complex and the RuCym bind 
parallel on HSA, the individual spectrum of the HSA-bound 
complex is unknown. In all, CZE and UV–vis data suggest 
the presence of some free RuCym(dhp) in samples con-
taining less than 0.2 eq of HSA, while negligible extent of 
free complex was registered in ultrafiltration experiments. 
Complex might stick on the filter in the latter case, although 
both RhCp* and RuCym complexes of dhp filtered alone 
displayed only 9% and 6% loss of compound in the filtered 
samples, respectively. RuCym(maltolato) complex displayed 
a similar behavior like RuCym(dhp) in ultrafiltration experi-
ments, except this complex bound considerably slower, as 
a results of the decomposition of the complex in ca. 29% 
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forming hydrolyzed [(RuCym))2(μ-OH)3]+ species under the 
experimental conditions.
Taking a look at Fig. 6/b, the interaction between HSA 
and RhCp*(pic) seems to take place according to the same 
scenario that was seen in case of RuCym(dhp). At the same 
time, there are important differences between the two sys-
tems: (i) binding of RhCp*(pic) proceeds much faster and 
(ii) pic itself can bind to the protein via intermolecular 
bonding [79]. The binding of pic to HSA is relatively weak; 
two low-affinity binding sites were identified formerly by 
spectrofluorometric measurements (see Table 1). Ultrafil-
tration studies confirmed the binding of at least one pic on 
HSA as well [79]. This way, the detected free pic in Fig. 6b 
does not correlate directly with the dissociated amount of 
RhCp*(pic) upon binding to HSA. Ultrafiltration and CZE 
studies provide similar fractions of free pic, while fractions 
of free complex differ somewhat at higher HSA-to-complex 
ratios. 1H NMR spectra in Fig. 9 indicate predominant 
binding of the metal species in complexed form at 1:0.5 
complex-to-HSA ratio and  C5Me5− proton signals are dif-
ferent from those of the bound organometallic cation (not 
shown here). In the case of RuCym(pic), signals of unbound 
complex were predominant in 1H NMR spectra of Fig. 9 in 
the presence of albumin after 24 h incubation time. CZE and 
ultrafiltration experiments confirmed lower affinity binding 
of this complex, and non-dissociated complex is assumed to 
bind mainly on the protein. UV–Vis studies showed minimal 
spectral changes in the presence of HSA, implying small, or 
no rearrangement in the coordination sphere of Ru(II) ion. 
Combining the results of the four techniques applied in this 
work, we can conclude that binding of the pic complex is 
thermodynamically less favored than in case of the other 
metal complexes studied. Similar tendencies were reported 
for RhCp*(ethylenediamine) and RhCp*(bpy) complexes in 
our former work, which were bound to a lower extent and 
retained their original structure [49].
Distribution diagrams in Fig. 6 provide further insight 
into the binding mechanism of the complexes. For exam-
ple, stabilization of free ligand fraction at ca. 20% for 
RuCym(dhp) and 25% for RhCp*(pic) in the presence of 
increasing amounts of HSA indicates an associative ligand 
exchange mechanism as shown in Chart 2, that was ascer-
tained for RuCym(dhp). Namely, metal complexes bind 
coordinatively (covalently) to the protein by displacement 
of the aqua (or chlorido) leaving group by protein donor 
atoms, and release of ligand at particular sites occurs while 
the protein coordinates with additional function(s) to the 
organometallic fragment to achieve thermodynamic equi-
librium. The equilibrium state is strongly affected by the 
solution stability of the original metal complex at pH 7.4 
and the stability of the forming HSA–metal ion adduct. 
This conception can be extended for albumin binding of 
RuCym(pic) and most probably for RhCp*(dhp) as well. 
Although the organometallic cation is ultimately bound in 
case of this complex, the maximal number of binding sites 
is much lower, about 8 ± 1 compared to the 24 ± 3 available 
sites in the case of RhCp* (Table 2). This finding confirms 
(a)
HSA+(b)
(b)
HSA+pic
pic
5.50.7 5.6 0.67.55.9 0.9 5.8 0.8
HSA
HSA+(a)
9.5     8.5   7.5   6.5    5.5
δ / ppm
Fig. 9  1H NMR spectra recorded for HSA and HSA–RhCp*(pic) 
(a) or RuCym(pic) (b) or pic systems (dotted frame denotes HSA-
bound pic complex, solid frame shows non-bound complex signals) 
[ccomplex = 1 mM, cHSA = 0.5 mM, PBS′, 10%  D2O]
Ru
Z
Z
N
O
HO
Cl/H2O/Z
ligand dissociationdonor atom substitution
Ru
O
N
O
RuH2O
O
N
O
ZZ
Z
associative binding
Ru
O
N
OZ
ZZ
Chart 2  Presumed mechanisms of binding of the studied metal com-
plexes on HSA. The initial step is monodentate coordination of a 
HSA donor atom displacing the leaving group  (H2O here) in the com-
plex. Dissociation of the bidentate ligand (dhp) is possible if a second 
donor atom of HSA is in coordinating position and is strong enough 
to replace the ligand. The binding of RuCym(dhp) is shown here, 
Z = donor atom of HSA
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the binding as metal complex (bearing clearly less available 
binding sites on HSA) and subsequent release of the ligand. 
Generally, the estimated number of available binding sites 
for the complexes is less compared to those of the organo-
metallic cations (see Table 2). Thermodynamic control in 
ligand release is seen well via the example of RhCp*(dhp) 
and RhCp*(pic), where pic complex, owing higher stability 
(Table S1), shows much less tendency to decompose upon 
binding to HSA-binding sites, while the dhp complex disso-
ciates completely in the presence of HSA. On the other hand, 
HSA-induced decomposition of the Ru complexes seems to 
be hindered kinetically, and observed fractions of free ligand 
(after 24 h incubation) represent only a temporary picture on 
ligand dissociation, which may take several days for the dhp 
complex and even more for the pic complex.
Interaction of the metal complexes in the hydrophobic 
pockets of HSA was investigated as well via the spectrofluo-
rometric technique. Kinetic studies showed fast (~ 10 min) 
binding of RhCp*(dhp), RhCp*(pic) and RuCym(dhp) at 
site I (IIA subdomain) corresponding well to the results 
of global binding studies. Computed binding constants of 
the metal complexes obtained by Trp-214 quenching and 
site marker probe displacement studies at sites I and II are 
listed in Table 1. In the case of lower stability complexes 
RhCp*(dhp), RuCym(maltolato) and RuCym(dhp), these 
constants are fairly similar to those of estimated for the 
corresponding organometallic cation, while elevated com-
plex stabilities lead to lower binding affinities at sites I and 
II. There is no reasonable difference between the binding 
affinities of the RhCp* complexes formed with picolinate 
derivatives, pic, 6-Mepic and 2-quinaldic acid (Chart 1) 
The more lipophilic character of the 2-quinaldic acid com-
plex has a minimal effect on the binding strength. Binding 
affinities of RhCp*–picolinate complexes at the hydropho-
bic binding sites are about one order of magnitude higher 
compared to those of RuCym(pic) and [Ru(η6-toluene)(pic)
(H2O)]+ [57].
Summarizing, a coordinative interaction of the studied 
complexes with HSA was found. Low stability and kineti-
cally labile complexes (e.g., RhCp*(dhp)) decompose to a 
high extent upon binding to the protein, while RhCp*-picoli-
nate-type ligand complexes of higher stabilities and the more 
inert RuCym complexes dissociate to a less extent. Similar 
tendencies were reported for Ru(arene) complexes interact-
ing with proteins due to the obtained results of X-ray diffrac-
tion method [42, 43, 86]: the interaction of presumably low 
stability complexes formed with (O,O) donor 3-hydroxy-
2-pyridone derivative ligands resulted in ligand release and 
two organoruthenium cations were coordinated by amino 
acid side chains (His-79 and His-106, Glu-102) of a histone 
protein [43]. At the same time, high-stability complexes 
of RuCym formed with ethylenediamine ((N,N) donor) 
and pyridine-thioamide type ((N,S) donor) ligands did not 
decompose and complexes are coordinated monodentately 
by His or Glu amino acid side chains [42, 86].
Reversibility of HSA binding and the effect 
of low‑molecular‑mass serum components
The reversible binding of a compound on serum proteins 
may have a profound effect on its pharmacokinetics and 
accumulation in solid tumor tissues. Thus, reversibility is 
a key feature, protein-bound and free fractions of a drug 
should be in equilibrium, otherwise irreversibly bound frac-
tions can easily decrease the effectiveness of a drug. First, 
the release of the bound organometallic cations, RhCp*(bpy) 
and WF, as a high-affinity binding ligand of HSA [87], was 
tested by consecutive ultrafiltration experiments. Figure 10 
shows free fractions of each compound. After the first wash-
ing cycle, RhCp*(bpy) was bound to HSA exclusively in 
an associative manner and to a lower extent compared to 
RhCp* in accordance with our former results [49]. In the 
next cycle, liberated portions of both organometallic com-
pounds remain under 10%, namely, binding of the organo-
metallic compounds seems to be at least partly reversible 
reaction, however, summed fraction of free RhCp* (25%) 
is ca. half of free WF (47%) after the fourth washing step.
Another interesting question is the fate of bound com-
pounds after denaturation of the protein, e.g., after entering 
an acidic vesicle in cells. It was tested in a model experi-
ment by the addition of SDS to the reaction mixtures 15 min 
prior to the filtration. SDS induces unfolding of the protein 
leading to the loss of specific sites providing intermolecular 
Table 2  Bound equivalents of the Rh and Ru compounds per HSA 
calculated on the basis of CZE measurements at HSA-to-compound 
ratios of 1: > 20
For metal complexes bound forms of the original complex (complex) 
and of the organometallic cation (metal ion) and their sum (Σ) are 
listed as well [25 °C, pH  7.40 (PBS′)]
a Calculated values are based on at least four measurements
b Calculated on basis of ultrafiltration measurements, see details in the 
Experimental Section
c Not measurable. Ligand pic binds on HSA as well, therefore values 
of bound complex and metal ion cannot be estimated, only the sum of 
them
HSA-to-compound ratio 1: > 20a
Bound form Complex Metal ion Σ
RhCp* – 24 ± 3b –
 dhp complex 0 8 ± 1 8 ± 1
 pic complex nmc nmc 12 ± 1
RuCym – 14 ± 1b –
 dhp complex 5 ± 0.7 4 ± 0.4 8 ± 0.6
 pic complex nmc nmc 4 ± 0.6
716 JBIC Journal of Biological Inorganic Chemistry (2019) 24:703–719
1 3
interactions for binding molecules. The last column set in 
Fig. 10 reveals (i) disintegration of site I resulting in 92% 
release of bound WF, (ii) coordinative binding mode of 
the bpy complex which seems to be facilitated by dena-
turation of albumin. RhCp* itself displays stronger binding 
to unfolded HSA, that most probably can be explained by 
the appearance of more available coordination sites. The 
same experiment was performed for 12- and 25-fold excess 
of RuCym and RhCp* to the protein, respectively. After 
removal of non-bound metal species, SDS was added, and 
less than 1% of RhCp* and RuCym were liberated, which 
strongly suggests that all bound organometallic cations inter-
act with HSA via coordinative bonds.
The altered binding nature of the organometallic ions and 
their various complexes to HSA was proven in the previ-
ous sections, at the same time exploring the competitive-
ness of low-molecular-mass serum components is a further 
important task. The effect of single LMM serum compounds 
on the albumin binding of the metal ions was followed by 
fluorescence quenching experiments focusing on the bind-
ing event at site I. Human serum contains numerous pos-
sible interacting partners for organometallic complexes. We 
have chosen, by their relatively high serum concentrations, 
serum components Ser (~ 100 μM), His (~ 77 μM), Met 
(~ 77 μM) and Cys (~ 33 μM); citric acid (~ 99 μM) and 
sodium lactate (~ 1.5 mM). Figure 11a shows the quenching 
effect of RuCym and RhCp* in the presence of these LMM 
serum components at two different experimental sets: once 
organometallic cations were mixed with LMM components 
and HSA was added, or cations pre-equilibrated with HSA 
(bound to site I) were treated with LMM compounds. In 
the first experimental set, LMM mixture interfered strongly 
with the quenching effect, i.e., the interaction of these cati-
ons with site I. While site I-bound organometallic species in 
the second set showed no (RuCym) or rather slow (RhCp*, 
several hours) interaction with LMM compounds. Measured 
intensities for RhCp* tend to show similar values irrespec-
tive of the order of component addition (see Figs. 11 and 
S7a), namely binding towards LMM compounds is a ther-
modynamically favored, but rather slow process in case of 
the albumin-bound metal, pointing out the kinetic aspects 
of this interaction. The effectivity of each LMM compound 
against site I for RhCp* coordination was investigated as 
well and it follows the trend: His ~ Met ~ Cys > Ser > cit-
rate ≥ lactate ~ buffer only. RuCym displays somewhat dif-
ferent preferences: citrate is as potent competitor as His and 
Cys; Met and Ser result in moderate quenching of fluores-
cence, while lactate has again no effect on binding at site I. 
The reaction is much slower for RuCym compared to RhCp* 
(see Fig. S7). Interestingly, addition of maltolato and dhp 
complexes of RuCym to the mixture of HSA and LMM com-
pounds resulted in a fast drop of Trp fluorescence to 75% 
and 50%, respectively, that was followed by an increase in 
intensity taking several hours (Fig. S8). It seems that these 
ligands act as carriers enabling competition of LMM com-
pounds for albumin-bound metal ions.
LMM components were applied here in their real serum 
concentration, but samples contained 1 μM HSA and tenfold 
excess of metallocompounds. Such a low concentration of 
HSA is due to the method requirements, but is much lower 
than the serum concentration. Taking into account this limi-
tation, our main conclusions are as follows: (i) LMM serum 
components may be effective competitors of site I in binding 
of the two organometallic cations, (ii) on the other hand, 
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Fig. 10  Free fractions of RhCp*, RhCp*(bpy) and WF in 1:1 HSA-
to-compound systems followed via ultrafiltration–UV–Vis after con-
secutive washing cycles or after denaturation of HSA (0.5% SDS) 
[ccomp = cHSA = 200 μM, PBS′, 25 °C]
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Fig. 11  Effect of an LMM component mixture on the quench-
ing efficacy of RhCp* (black) and RuCym (gray) at binding site I 
by addition of LMM compounds before (left side) or after (right 
side) equilibration of metallocompounds with HSA [cHSA = 1  μM; 
cRh = cRu = 10  μM; cLMM components = 77  μM (His), 23  μM (Met), 
33  μM, (Cys), 100  μM (Ser), 99  μM (citrate), 1.5  mM (lactate); 
λEX = 295  nm, λEM = 350  nm; pre-equilibration = 2  h (Rh) or 30  h 
(Ru)]
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protein-bound cations are hardly accessible for LMM com-
petitors owing to kinetic reasons. Former conclusions most 
probably can be extended for further binding sites on HSA, 
since results of quenching experiments presented in former 
sections revealed both kinetic and thermodynamic similari-
ties of site I to the average binding sites characterized in 
global binding studies. Applying strictly oxygen-free condi-
tions, Cys showed itself to be a potent binder of both organo-
metallic cations. The carrier-like effect of bidentate ligands 
maltol and dhp on the site I binding of RuCym requires more 
detailed investigations in the future.
Conclusions
In this work, the binding interactions between half-sandwich 
organorhodium and organoruthenium compounds and HSA 
were investigated by means of separation techniques, ultrafil-
tration and CZE, and spectroscopic methods, UV–Vis spec-
trophotometry, spectrofluorometry and 1H NMR. Albumin 
binding of organometallic ions RhCp* and RuCym and their 
dhp and pic complexes with different thermodynamic sta-
bility and kinetic properties was investigated in first line. 
Kinetic aspects, binding strength and location, the nature 
and reversibility of these interactions were discussed. Low 
stability RuCym(maltolato), and complexes of picolinate 
derivatives 6-Mepic and 2-quinaldic acid formed with 
RhCp* were also included in our investigations to obtain 
more information on the relevant physico-chemical param-
eters having an effect on the nature and extent of binding.
Studies in RPMI cell culture medium pointed out the sig-
nificant decomposition of the complexes RhCp*(dhp) and 
RhCp*(pic) due to the interaction with medium components 
(mainly amino acids). Consequently, cytotoxicity measured 
for lower stability complexes corresponds to the sum of effi-
cacy measured for the metal ion and the ligand separately.
RuCym and RhCp* can bind to HSA in high extent 
(14 ± 1 and 24 ± 3 eq per protein, respectively) via coordi-
native interactions preferably with N-donor atoms of HSA. 
RhCp* interacts with HSA in few minutes, while binding 
of RuCym takes about 24 h. Binding of RuCym(dhp) and 
RuCym(maltolato) complexes however is much faster.
Metal complexes studied display different binding modes. 
Our results suggest the following mechanism for albumin 
binding: as initial step a protein donor atom coordinates 
monodentately to the metal center replacing the aqua (or 
chlorido) leaving group in the metal complex (associative 
binding), that is optionally followed by coordination of 
additional protein donor atom(s) and consecutive release 
of the original ligand (dissociative binding). The binding 
mechanism is governed by the thermodynamic stability and 
kinetic inertness of the complexes; lower stability and labile 
complexes (e.g. RhCp*(dhp)) bind in dissociative manner 
to HSA, while in the case of highly stable and more inert 
compound RuCym(pic) associative binding is predominant. 
Complexes RuCym(dhp) and RhCp*(pic) interact with HSA 
both in associative and dissociative manner.
All of the studied compounds interact at the hydropho-
bic binding sites I and II of HSA and most probably bind-
ing via complex dissociation is favored. Adduct formation 
at these sites may become relevant by interfering the blood 
transport of other molecules bound here.
The maximal bound number of metal complexes on HSA 
varies within 4 and 14, however at physiological concentra-
tions, namely at high HSA excess, complete binding and 
formation of only 1:1 adducts is expected. HSA binding of 
RuCym, RhCp* and their low stability complexes is hindered 
at site I in the presence of LMM serum compounds being 
able to coordinate to the organometallic ions. The most rel-
evant LMM competitors of HSA are His, Met and Cys for 
both metal ions. At the same time, HSA-bound cations are 
hardly accessible for LMM chelators owing to kinetic reasons. 
Denaturation of the protein does not lead to the release of the 
organometallic ions and RhCp*(bpy), on the contrary, bound 
fractions increased, because of the appearance of new acces-
sible coordinating sites. This phenomenon raises the question 
whether HSA can deliver these organometallic compounds 
or serves as a less available pool for them. This is currently 
investigated in our laboratory. The great number of accessible 
binding sites providing coordinative interactions for the stud-
ied metal ions and their complexes is not a specific feature of 
albumin, most probably numerous different types of proteins 
can interact with these compounds in similar manner to HSA. 
In this way organorhodium and organoruthenium complexes 
being able to form coordinative bond(s) rapidly with proteins 
may lead to decrease of effective drug concentration and may 
be responsible for adverse effects as well.
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